Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical Practice (DEVOTE)

Status:

Closed to Accrual

Observational

Phase

N/A

Line of Therapy

Any Stage

Disease Stage

Biomarker(s)

N/A

Investigational

Product

Venetoclax

Antineoplastic Agent; BCL-2 Inhibitor (p.o.)

Treatment Arms

o Participants receiving venetoclax